In The Spotlight
DDNews Cancer Research Exclusive
Recent work with nanoparticles offers a new approach to photo-thermal cancer therapies
(Photo credit: University of Toronto)
The PEARLs (Photothermal Enhancing Auto-Regulated Liposomes) were developed by Dr. Gang Zheng of the Princess Margaret Cancer Centre and University of Toronto and colleagues, who say they overcome traditional roadblocks to penetrate deeper into tumors.
Cancer Research UK and Newcastle University extend discovery alliance with Astex
Five Prime Therapeutics Inc. presented an oral poster discussion recently at the European Society for Medical Oncology (ESMO) 2017 Congress on FPA150, its novel B7-H4 therapeutic antibody
Clinical Genomics and QIAGEN partner on liquid biopsies to diagnose recurrence of colorectal cancer
Researchers use fluorescent sensors to elucidate GTP activity in cells
A roundup of recent research and clinical work within the realm of breast cancer, as well as substantial coverage of immuno-oncology and other cancer areas
Gilead secures Kite Pharma for $11.9B in second-largest deal of 2017
Compugen shares data supporting CGEN-15032 as an immuno-oncology target and expands collaboration with Johns Hopkins
Lilly’s MONARCH 3 study published in Journal of Clinical Oncology demonstrates benefit of abemaciclib plus NSAI in advanced breast cancer
(Photo credit: NCI, NIH)
The latest Annual Report to the Nation shares that cancer survival rates are rising, while incidence and death rates are on a downward trend
by JK Bryan & A Zupnick, Novella
When it comes to oncology clinical trials, drug developers need to stay abreast of the rapidly evolving and competitive landscape while also remaining flexible and innovative in responding to these changes

by Dr. Alexey Eliseev, RXi
The “War on Cancer” declared by the National Cancer Act of 1971 proceeded through a series of evolutionary developments in chemotherapy, radiation treatments and targeted therapies, but until recently was only marginally successful in extending the lives of late-stage cancer patients. A major breakthrough has been achieved over the last decade with the development of immunotherapeutic treatments that empower a patient’s own immune cells to destroy tumors

by Dr. Brad Thompson, Oncolytics
During these heady and still-early days in the age of clinical studies involving immunotherapy, it is useful to ponder some of the outstanding questions these studies raise

Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.